Papaloisou to market Elidel cream in Cyprus
Date: 27 Jun 2012

The Swedish pharmaceutical company MEDA AB and C.G. Papaloisou Ltd have commenced marketing and distribution of ElidelĀ® cream 10mg/g (pimecrolimus). Elidel is a patent protected product for the treatment of atopic dermatitis (AD). AD is a chronically relapsing inflammatory skin disease and the skin barrier plays an essential role in protection against AD flares. Elidel is the first non-steroidal topical cream treatment specifically developed for the treatment of AD.

Meda acquired the global rights for Elidel from Novartis in 2011.

More information about Elidel click here.